OTCMKTS:PRTX - Protalex Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.3799 -0.17 (-30.91 %) (As of 07/19/2018 06:00 AM ET)Previous Close$0.55Today's Range$0.3799 - $0.5552-Week Range$0.3120 - $3.00Volume19,480 shsAverage Volume1,502 shsMarket Capitalization$17.98 millionP/E RatioN/ADividend YieldN/ABeta1.25 Company ProfileFinancialsEarnings HistoryInsider TradesHeadlinesSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protalex, Inc. focuses on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, a formulation of a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey. Receive PRTX News and Ratings via Email Sign-up to receive the latest news and ratings for PRTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical SymbolOTCMKTS:PRTX CUSIPN/A Webwww.protalex.com Phone215-862-9720 Debt Debt-to-Equity Ratio-1.66 Current Ratio2.03 Quick Ratio2.03 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value($0.76) per share Price / Book-0.50 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,560,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-654.38% Miscellaneous Employees2 Outstanding Shares47,330,000Market Cap$17.98 Protalex (OTCMKTS:PRTX) Frequently Asked Questions What is Protalex's stock symbol? Protalex trades on the OTCMKTS under the ticker symbol "PRTX." How were Protalex's earnings last quarter? Protalex Inc. (OTCMKTS:PRTX) posted its quarterly earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share for the quarter. View Protalex's Earnings History. When is Protalex's next earnings date? Protalex is scheduled to release their next quarterly earnings announcement on Friday, July, 20th 2018. View Earnings Estimates for Protalex. What is the consensus analysts' recommendation for Protalex? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalex in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Protalex's key competitors? Some companies that are related to Protalex include Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Tenax Therapeutics (TENX), Geovax Labs (GOVX), ALGAE TEC Ltd/S (ALGXY) and Redpoint Bio (RPBC). Who are Protalex's key executives? Protalex's management team includes the folowing people: Mr. Arnold P. Kling Esq., Pres and Director (Age 60)Mr. Kirk M. Warshaw, Chief Financial Officer, Sec. and Director (Age 60)Dr. William E. Gannon JR., M.D., M.B.A., Chief Medical Officer & Member of Scientific Advisory BoardDr. John Bruce Lundy McClain M.D., Medical Director & Member of Scientific Advisory BoardDr. Richard J. Francovitch Ph.D., VP of ITP Program & Member of Scientific Advisory Board Has Protalex been receiving favorable news coverage? News headlines about PRTX stock have been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Protalex earned a media sentiment score of 0.13 on Accern's scale. They also gave press coverage about the company an impact score of 46.38 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. How do I buy shares of Protalex? Shares of PRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protalex's stock price today? One share of PRTX stock can currently be purchased for approximately $0.3799. How big of a company is Protalex? Protalex has a market capitalization of $17.98 million. Protalex employs 2 workers across the globe. How can I contact Protalex? Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected] MarketBeat Community Rating for Protalex (OTCMKTS PRTX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 42 (Vote Outperform)Underperform Votes: 37 (Vote Underperform)Total Votes: 79MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe PRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?